| TITLE |
DATE |
| Amgen to Present at the 22nd Annual Oppenheimer Healthcare Conference |
9-Dec-2011 |
| Amgen Announces Preliminary Results of Its Tender Offer |
8-Dec-2011 |
| Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy |
6-Dec-2011 |
| Enbrel® (etanercept) Patent Issued |
22-Nov-2011 |
| The Lancet Publishes Results Demonstrating XGEVA® Significantly Prolonged Bone Metastasis-free Survival in Men With Prostate Cancer |
15-Nov-2011 |
| Vectibix® (Panitumumab) Granted Approval for Expanded Indications in the European Union |
15-Nov-2011 |
| Amgen Statement on European Investor Visit |
14-Nov-2011 |
| Amgen Announces Plan to Launch Tender Offer and Launch of Senior Notes Offering |
7-Nov-2011 |
| Treatment With Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients With Moderately Active Disease |
5-Nov-2011 |
| Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Six Years With Similar Safety Profile Observed in Original Fracture Trial |
5-Nov-2011 |
| Amgen's Third Quarter 2011 Revenue and Adjusted Earnings Per Share (EPS) Each Increased 3 Percent to $3.9 Billion and $1.40 |
24-Oct-2011 |
| Amgen Announces Webcast of 2011 Third Quarter Financial Results |
19-Oct-2011 |
| Amgen Appoints Anthony (Tony) Hooper Executive Vice President Global Commercial Operations |
19-Oct-2011 |
| Amgen Appoints Robert A. Bradway to the Company's Board of Directors |
13-Oct-2011 |
| Amgen Announces 2011 Fourth Quarter Dividend |
13-Oct-2011 |
| Amgen Highlights Data to be Presented at 2011 European Multidisciplinary Cancer Congress |
23-Sep-2011 |
| FDA Approves New Indications for Prolia® (Denosumab) for the Treatment of Bone Loss in Patients With Prostate or Breast Cancer Undergoing Hormone Ablation Therapy |
19-Sep-2011 |
| Prolia® (Denosumab) Phase 2 Extension Study Showed Continued Increase in Bone Mineral Density Over Eight Years of Treatment |
17-Sep-2011 |
| Amgen to Present at the UBS Global Life Sciences Conference |
15-Sep-2011 |
| Amgen Staff Volunteer Efforts Result in $5,000 For Each of Their Favorite Nonprofits |
15-Sep-2011 |
| Amgen to Present at the Bank of America Merrill Lynch Global Healthcare Conference |
12-Sep-2011 |
| Amgen to Present at the Morgan Stanley Global Healthcare Conference |
8-Sep-2011 |
| Amgen to Present at the Baird Healthcare Conference |
6-Sep-2011 |
| Amgen to Present at the Stifel Nicolaus Healthcare Conference |
2-Sep-2011 |
| Award-Winning Actress Blythe Danner and Amgen Launch Act 2 Reduce Fractures(TM) Educational Campaign |
25-Aug-2011 |
| Amgen Announces PDUFA Date for XGEVA® Supplemental Biologics License Application |
22-Aug-2011 |
| Amgen Highlights Data to Be Presented at American Society for Bone and Mineral Research Meeting |
18-Aug-2011 |
| Amgen's Second Quarter 2011 Revenue Increased 4 Percent to $4.0 Billion |
29-Jul-2011 |
| Amgen Announces Webcast of 2011 Second Quarter Financial Results |
25-Jul-2011 |
| Amgen Resolves G-CSF Patent Litigation With Teva |
15-Jul-2011 |
| XGEVA® (Denosumab) Granted Marketing Authorization in the European Union |
15-Jul-2011 |
| Amgen and UCB Team Up With NASA on Final Space Shuttle Mission to Conduct Preclinical Test of Sclerostin Antibody on Bone Loss |
5-Jul-2011 |
| Amgen Submits Application to Expand Indication for XGEVA® (Denosumab) to Prevent or Delay Spread of Prostate Cancer to the Bone |
27-Jun-2011 |
| Notice to Investors Regarding 2011 and 2015 Guidance |
24-Jun-2011 |
| Amgen Announces Modifications to U.S. Prescribing Information for Use of Erythropoiesis-Stimulating Agents in Chronic Kidney Disease |
24-Jun-2011 |
| Amgen Receives Positive CHMP Opinion for Vectibix® (Panitumumab) in Combination With Chemotherapy |
24-Jun-2011 |
| Teachers and Schools Across North America Receive $10,000 Amgen Award for Science Teaching Excellence |
21-Jun-2011 |
| Data Presented at Two Global Medical Congresses Reinforce Benefit of Enbrel(R) (etanercept) for Patients with Chronic Inflammatory Conditions |
25-May-2011 |
| Amgen Announces Voting Results Of Annual Meeting of Stockholders |
20-May-2011 |
| Amgen Receives CHMP Positive Opinion for XGEVA(TM) (Denosumab) in the European Union |
20-May-2011 |
| Amgen Oncology Data to be Presented at ASCO Annual Meeting |
18-May-2011 |
| Phase 3 Data Demonstrate XGEVA(TM) (Denosumab) is First Bone Targeted Therapy to Prevent Spread of Cancer to the Bone in Men With Advanced Prostate Cancer |
17-May-2011 |
| Amgen to Webcast Investor Meeting at Upcoming American Urological Association Conference |
13-May-2011 |
| Patrick Dempsey Teams up With Breakaway from Cancer(R) to Help Connect Cancer Patients to Free Resources |
11-May-2011 |
| Five Californians Selected as Breakaway from Cancer(R) Champions to be Honored During Amgen Tour of California |
10-May-2011 |
| Amgen to Present at the Deutsche Bank 36th Annual Healthcare Conference |
28-Apr-2011 |
| Amgen Outlines Strategy, Growth Objectives and Capital Allocation Plans |
21-Apr-2011 |
| Amgen and UCB Announce Positive Phase 2 Results of AMG 785/CDP7851 in Patients With Postmenopausal Osteoporosis (PMO) |
21-Apr-2011 |
| Amgen's First Quarter 2011 Revenue Increased 3 Percent to $3.7 Billion |
20-Apr-2011 |
| Amgen to Webcast 2011 Business Review Meeting on April 21 |
14-Apr-2011 |
| Amgen Announces Webcast of 2011 First Quarter Financial Results |
13-Apr-2011 |
| Amgen Establishes Commercial Operations in Brazil |
8-Apr-2011 |
| Amgen to Appeal CHMP Opinion on Vectibix(R) (Panitumumab) Use With Chemotherapy in Metastatic Colorectal Cancer in Europe |
30-Mar-2011 |
| Top-Line Results Announced of Pivotal Phase 3 Motesanib Trial in Advanced Non-Squamous Non-Small Cell Lung Cancer Patients |
30-Mar-2011 |
| Prolia(R) (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Five Years of Treatment With Similar Safety Profile Observed in Pivotal Trial |
23-Mar-2011 |
| Treatment With Prolia(R) (denosumab) Associated With Significantly Greater Adherence, Compliance and Persistence Compared to Alendronate |
23-Mar-2011 |
| Amgen Statement on CHMP Opinion on Vectibix(R) (Panitumumab) Use With Chemotherapy in Metastatic Colorectal Cancer |
18-Mar-2011 |
| Amgen Donates $1 Million to Help Japanese Disaster Victims |
14-Mar-2011 |
| Amgen Completes Acquisition of BioVex |
4-Mar-2011 |
| Amgen to Present at the Cowen and Company 31st Annual Healthcare Conference |
3-Mar-2011 |
| Breakaway From Cancer(R) Launches Newly-Enhanced Website Offering Comprehensive, Tailored Support for Cancer Patients |
3-Mar-2011 |
| World-Class Professional Golfer Phil Mickelson Launches 'On Course with Phil' for People with Certain Inflammatory Joint and Skin Conditions |
2-Mar-2011 |
| NBPTS and Amgen Foundation Join to Bolster Science Education |
1-Mar-2011 |
| Results Published in The Lancet Demonstrate Superiority of XGEVA(TM) (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer |
24-Feb-2011 |
| Amgen to Present at the Citi 2011 Global Healthcare Conference |
24-Feb-2011 |
| The Journal of Clinical Oncology Publishes Phase 3 XGEVA(TM) (Denosumab) Results in Advanced Cancer Patients With Solid Tumors or Multiple Myeloma |
22-Feb-2011 |
| Enbrel(R) (etanercept) Significantly Improved Scalp Involvement in Patients with Moderate to Severe Plaque Psoriasis |
4-Feb-2011 |
| Amgen to Acquire BioVex, a Privately Held Biotechnology Company Headquartered in Woburn, Mass |
24-Jan-2011 |
| Amgen's Fourth Quarter 2010 Adjusted Earnings Per Share Increased 11 Percent to $1.17; Full Year 2010 Adjusted Earnings Per Share Increased 6 Percent to $5.21 |
24-Jan-2011 |
| Amgen Announces Webcast of 2010 Fourth Quarter and Full Year Financial Results |
24-Jan-2011 |
| Boehringer Ingelheim to Purchase Amgen's Fremont (California) Facility |
18-Jan-2011 |
| Sensipar(R) Patents Upheld By District Court |
7-Jan-2011 |
| Amgen to Present at the 29th Annual JP Morgan Healthcare Conference |
6-Jan-2011 |
| Amgen and Xencor Enter Option Deal to Co-Develop Xencor's Novel Antibody for Autoimmune Diseases |
6-Jan-2011 |
| Teach For America and the Amgen Foundation Renew Partnership to Improve Math and Science Education in Urban and Rural Schools |
16-Dec-2010 |
| XGEVA(TM) (Denosumab) Significantly Improved Bone Metastasis-Free Survival in Men With Prostate Cancer |
13-Dec-2010 |
| Amgen Presents New XGEVA(TM) (Denosumab) Breast Cancer Skeletal-Related Event Prevention Data at SABCS |
10-Dec-2010 |
| Amgen to Present at Deutsche Bank's 2010 BioFEST |
8-Dec-2010 |
| Three Innovative Ideas Receive $10,000 Prizes in Patients | Choices | Empowerment Competition |
8-Dec-2010 |
| Amgen's Nplate(R) Maintains Platelet Counts for More Than Five Years in Adults With Chronic ITP |
5-Dec-2010 |
| Amgen Highlights Data to Be Presented at American Society of Hematology Annual Meeting |
2-Dec-2010 |
| FDA Approves Amgen's XGEVA(TM) (Denosumab) for the Prevention of Skeletal-Related Events in Patients with Bone Metastases from Solid Tumors |
18-Nov-2010 |
| Amgen Foundation and Ashoka's Changemakers Announce Finalists in Patients | Choices | Empowerment Competition |
17-Nov-2010 |
| Call for Applications: The Amgen Award for Science Teaching Excellence |
16-Nov-2010 |
| Amgen Foundation Recognizes Outstanding Staff Volunteers and Contributes $55,000 to Their Favorite Local Nonprofits |
11-Nov-2010 |
| Study Published in New England Journal of Medicine Shows Nplate(R) Significantly Reduces Treatment Failure and Splenectomy Rate in Patients With Chronic ITP |
10-Nov-2010 |
| Amgen Scholars Undergraduate Summer Research Program Begins Phase 2 |
10-Nov-2010 |
| Amgen to Present at 19th Annual Credit Suisse Healthcare Conference |
9-Nov-2010 |
| Published Results Show Denosumab Superior to Zometa(R) in Delaying or Preventing Bone Complications in Patients With Bone Metastases From Advanced Breast Cancer |
8-Nov-2010 |
| Amgen, Pfizer, and World-Class Professional Golfer Phil Mickelson Announce Partnership |
6-Nov-2010 |
| Prolia(TM) (denosumab) Receives Best New Drug Honor at Scrip Awards |
5-Nov-2010 |
| Amgen Foundation Awards $4.5 Million Grant to MLA Partner Schools to Invest in LA's Promise |
3-Nov-2010 |
| Amgen to Provide Testimony at FDA Hearing on Biosimilars |
1-Nov-2010 |
| Amgen's Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year |
25-Oct-2010 |
| Breakaway From Cancer(R) Launches 'Striking the Balance' Podcast Series to Inspire Action and Change Across the Cancer Continuum |
20-Oct-2010 |
| Amgen Announces Webcast of 2010 Third Quarter Financial Results |
20-Oct-2010 |
| Amgen to Review Results From TREAT and Propose Updates to ESA Labeling for Chronic Renal Failure Patients at an FDA Advisory Committee Meeting Today |
18-Oct-2010 |
| Amgen Highlights Data to Be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting |
14-Oct-2010 |
| Integrated Analysis Demonstrates That Denosumab Delays the Onset of Bone Complications Compared to Zometa(R) |
10-Oct-2010 |
| Updated AMG 386 Data Demonstrate Promising Antitumor Activity in Patients With Recurrent Ovarian Cancer |
9-Oct-2010 |
| Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress |
5-Oct-2010 |
| Two Pivotal Vectibix(R) Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology |
4-Oct-2010 |
| Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN(R) and PROCRIT(R) (Epoetin alfa) |
24-Sep-2010 |
| Amgen and Pfizer Introduce 'Psophisticated Style: A Guide to Everyday Style and Psoriasis(TM)' Hosted by Tim Gunn |
22-Sep-2010 |
| Amgen to Present at the UBS Global Life Sciences Conference |
20-Sep-2010 |
| Amgen to Present at the Bank of America Merrill Lynch Global Healthcare Conference |
14-Sep-2010 |
| Amgen to Present at the Baird Healthcare Conference |
13-Sep-2010 |
| Amgen Announces Top-Line Results of Phase 3 Head and Neck Cancer Trial |
11-Aug-2010 |
| Amgen's Second Quarter 2010 Adjusted Earnings Per Share Increased 7 Percent to $1.38 |
29-Jul-2010 |
| 2010 Addressing Psoriasis(TM) Contest Winners Attend a Style Consultation with Tim Gunn in New York City |
28-Jul-2010 |
| Amgen Announces Webcast of 2010 Second Quarter Financial Results |
26-Jul-2010 |
| Amgen Appoints Ronald D. Sugar to the Company's Board of Directors |
22-Jul-2010 |
| Amgen Scholars' Summer Research Helps Lead to Science Careers |
19-Jul-2010 |
| FDA Grants Priority Review Designation to Denosumab Biologics License Application for the Reduction of Skeletal Related Events in Advanced Cancer Patients |
16-Jul-2010 |
| Amgen Appoints Jonathan M. Peacock Executive Vice President and Chief Financial Officer |
15-Jul-2010 |
| Amgen Foundation and Changemakers Launch Global Online Competition to Empower Patients for Better Outcomes |
14-Jul-2010 |
| 34 Teachers and Schools Across North America Receive $10,000 Amgen Award for Science Teaching Excellence |
22-Jun-2010 |
| Amgen to Present at the Goldman Sachs Global Healthcare Conference |
15-Jun-2010 |
| Amgen to Present at the Jeffries Global Life Sciences Conference |
7-Jun-2010 |
| New AMG 386 Data Demonstrate Promising Antitumor Activity in Patients With Recurrent Ovarian Cancer |
6-Jun-2010 |
| Striking the Balance: Community Experts Come Together for High-Level Dialogue on Cancer Care |
5-Jun-2010 |
| Denosumab Demonstrated Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Prostate Cancer |
5-Jun-2010 |
| New Analyses of Denosumab Pivotal Phase 3 Trials Reinforce Potential Advantages Over Standard of Care |
5-Jun-2010 |
| New AMG 479 Phase 2 Data Show Antitumor Activity in Patients With Metastatic Pancreatic Cancer |
4-Jun-2010 |
| FDA Approves Amgen's Prolia(TM) (Denosumab) for Treatment of Postmenopausal Women With Osteoporosis at High Risk for Fracture |
1-Jun-2010 |
| Prolia(R) (Denosumab) Granted Marketing Authorization in the European Union |
28-May-2010 |
| Amgen Highlights Key Clinical Data to Be Presented at American Society of Clinical Oncology Annual Meeting |
20-May-2010 |
| Amgen Submits Denosumab Biologics License Application to FDA for the Reduction of Skeletal Related Events in Cancer Patients |
14-May-2010 |
| Amgen Announces Voting Results of Annual Meeting of Stockholders |
12-May-2010 |
| Amgen's Breakaway From Cancer(R) to Honor Cancer Survivors at Amgen Tour of California |
11-May-2010 |
| Amgen Scientists Visit Biotechnology Classrooms Across the Country in Support of National Lab Day |
6-May-2010 |
| Amgen to Present at the Deutsche Bank 35th Annual Healthcare Conference |
29-Apr-2010 |
| Amgen Appoints Robert A. Bradway President and Chief Operating Officer |
26-Apr-2010 |
| Amgen's First Quarter 2010 Adjusted Earnings Per Share Increased 20 Percent to $1.30 |
21-Apr-2010 |
| Amgen Announces Webcast of 2010 First Quarter Financial Results |
19-Apr-2010 |
| Amgen Preclinical Study Demonstrated Anti-Tumor Activity in Mammary Tumor Model |
19-Apr-2010 |
| Analysis of Vectibix(R) Study Using New Gene Technology Helps to Advance Prospects for Personalized Medicine |
18-Apr-2010 |
| Amgen Highlights Biomarker and Preclinical Data to be Presented at American Association for Cancer Research (AACR) Annual Meeting |
12-Apr-2010 |
| Amgen to Present at the Cowen and Company 30th Annual Healthcare Conference |
8-Mar-2010 |
| 'Project Runway's' Tim Gunn Returns to Address Psoriasis(TM) and Empower Patients to be Confident in Their Personal Style |
3-Mar-2010 |
| FDA Classifies Prolia(TM) (Denosumab) Complete Response Submission and Targets Action Date |
19-Feb-2010 |
| Amgen and Centocor Ortho Biotech Products Finalize ESA Risk Evaluation and Mitigation Strategy (REMS) With FDA |
16-Feb-2010 |
| Denosumab Demonstrated Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Prostate Cancer Patients With Bone Metastases |
8-Feb-2010 |
| Amgen's Fourth Quarter 2009 Adjusted Earnings Per Share Decreased 1 Percent to $1.05; Full Year 2009 Adjusted Earnings Per Share Increased 8 Percent to $4.91 |
25-Jan-2010 |
| Amgen Presents Complete Results From Two Pivotal Phase 3 Studies of Vectibix(R) at Gastrointestinal Cancers Symposium |
21-Jan-2010 |
| Amgen Announces Webcast of 2009 Fourth Quarter and Full Year Financial Results |
20-Jan-2010 |
| Amgen Donates $2 Million, Establishes Earthquake Relief Program |
14-Jan-2010 |
| Amgen to Present at the 28th Annual JP Morgan Healthcare Conference |
7-Jan-2010 |
| Amgen Resolves EPO Patent Dispute With Roche |
22-Dec-2009 |
| Amgen's Roger M. Perlmutter, M.D., Ph.D., Named 2009 AAAS Fellow, Recognized for Discovery, Development of Novel Medicines |
18-Dec-2009 |
| Amgen Receives CHMP Positive Opinion for Prolia(TM) (Denosumab) in the European Union |
18-Dec-2009 |
| Array BioPharma and Amgen Partner in Type 2 Diabetes |
14-Dec-2009 |
| NEW STUDY RESULTS PRESENTED AT 2009 SAN ANTONIO BREAST CANCER SYMPOSIUM SHOW IMPORTANCE OF PROTECTING YOUR BONES |
10-Dec-2009 |
| Data Presented at San Antonio Breast Cancer Symposium Demonstrate Treatment with Denosumab is Superior to the Standard of Care |
10-Dec-2009 |
| Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP |
7-Dec-2009 |
| Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program |
7-Dec-2009 |
| New Amgen Scholars Web site Launches to Build a Global Network for Future Scientists |
3-Dec-2009 |
| Amgen Highlights Data to be Presented at ASH |
30-Nov-2009 |
| Amgen Recognized for Best Pipeline and Best New Drug at Scrip Awards |
23-Nov-2009 |
| Amgen to Present at Lazard Capital Healthcare Conference |
16-Nov-2009 |
| Amgen to Present at 18th Annual Credit Suisse Healthcare Conference |
12-Nov-2009 |
| Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer |
5-Nov-2009 |
| Call for Applications: The Amgen Award for Science Teaching Excellence |
4-Nov-2009 |
| Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Primary Efficacy Endpoints |
30-Oct-2009 |
| Amgen's Third Quarter 2009 Adjusted Earnings Per Share Increased 21 Percent to $1.49 |
21-Oct-2009 |
| Amgen Provides Update on Status of Prolia(TM) (Denosumab) Biologics License Application (BLA) Submitted to the U.S. Food and Drug Administration (FDA) |
19-Oct-2009 |
| Enbrel(R) (etanercept) Data to be Presented at the 2009 American College of Rheumatology Scientific Meeting |
16-Oct-2009 |
| Amgen Announces Webcast of 2009 Third Quarter Financial Results |
15-Oct-2009 |
| Vectibix(R) in Combination With Chemotherapy Significantly Improves Progression-Free Survival in First-Line Metastatic Colorectal Cancer |
24-Sep-2009 |
| Denosumab Demonstrates Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer Patients |
22-Sep-2009 |
| Vectibix(R) in Combination With Chemotherapy Significantly Improves Progression-Free Survival in Second-Line Metastatic Colorectal Cancer |
22-Sep-2009 |
| Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases |
21-Sep-2009 |
| Amgen to Present at the UBS Global Life Sciences Conference |
17-Sep-2009 |
| Amgen to Present Pivotal Data From Four Phase 3 Studies at the ECCO 15 - ESMO 34 Congress |
16-Sep-2009 |
| Amgen Scholars Europe Programme Convenes Undergraduates From 15 Countries for Innovative Science Research |
16-Sep-2009 |
| Appeals Court Affirms Patent Infringement Rulings Against Roche's peg-EPO Product |
15-Sep-2009 |
| Amgen to Present at the Bank of America Merrill Lynch Global Healthcare Conference |
14-Sep-2009 |
| Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis |
13-Sep-2009 |
| Amgen to Present at the Morgan Stanley Global Healthcare Unplugged Conference |
11-Sep-2009 |
| Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting |
10-Sep-2009 |
| Edie Falco and Cynthia Nixon Appear in New Stand Up To Cancer(TM) PSAs Designed to Educate Cancer Patients About the Importance Of Lowering One's Risk of Infection During Treatment |
10-Sep-2009 |
| Amgen Named Presenting Sponsor of The Dempsey Challenge: A Journey For Hope |
9-Sep-2009 |
| Amgen to Present at the Thomas Weisel Healthcare Conference |
8-Sep-2009 |
| Amgen to Present at the Baird Healthcare Conference |
4-Sep-2009 |
| Tim Gunn Hosts Addressing Psoriasis(TM) Fashion Show to Raise Awareness of Psoriasis |
2-Sep-2009 |
| Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes |
25-Aug-2009 |
| Vectibix(R) Significantly Improved Progression-Free Survival in Second-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer |
17-Aug-2009 |
| Amgen Issues Statement on Outcomes of Advisory Committee for Reproductive Health Drugs (ACRHD) Meeting |
13-Aug-2009 |
| Amgen to Discuss Denosumab Data at Today's Advisory Committee for Reproductive Health Drugs |
13-Aug-2009 |
| Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss |
11-Aug-2009 |
| Vectibix(R) in Combination With Chemotherapy Significantly Improved Progression-Free Survival in First-Line Metastatic Colorectal Cancer |
6-Aug-2009 |
| Amgen and Wyeth Statement on FDA Announcement About Tumor Necrosis Factor (TNF) Blockers |
4-Aug-2009 |
| Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R) |
3-Aug-2009 |
| Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO) |
27-Jul-2009 |
| Amgen's Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To $1.29 |
27-Jul-2009 |
| Amgen Announces Webcast of 2009 Second Quarter Financial Results |
23-Jul-2009 |
| Amgen Scholars Discover Their Potential During Summer Science Research Program and National Symposium |
20-Jul-2009 |
| Amgen Announces KRAS Safety Update to U.S. Prescribing Information for Vectibix(R) (Panitumumab) |
17-Jul-2009 |
| Amgen Appoints Rebecca M. Henderson to the Company's Board of Directors |
9-Jul-2009 |
| Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases |
7-Jul-2009 |
| Winners of the Addressing Psoriasis(TM) Contest Selected to Walk the Runway in New York City Fashion Show Hosted by Tim Gunn |
6-Jul-2009 |
| Amgen to Participate in Reproductive Health Drugs Advisory Committee Meeting in August |
22-Jun-2009 |
| 34 Outstanding Teachers and Schools Receive $10,000 Amgen Award for Science Teaching Excellence |
17-Jun-2009 |
| Amgen to Present at the Goldman Sachs Global Healthcare Conference |
8-Jun-2009 |
| New Study Shows Nplate(R) Significantly Reduces Splenectomy Rate and Treatment Failure in Patients With Chronic ITP |
7-Jun-2009 |
| VIDEO from Medialink and Amgen: New Survey Highlights Growing Concern About Risk of Infection and Emerging Antibiotic Resistance in Cancer Patients |
27-May-2009 |
| New Survey Highlights Growing Concern About Risk of Infection in Cancer Patients and Emerging Antibiotic Resistance |
27-May-2009 |
| Amgen Exercises Option for Exclusive License to Cytokinetics' Cardiac Contractility Program That Includes CK-1827452 |
26-May-2009 |
| Amgen Highlights Data to Be Presented at ASCO |
15-May-2009 |
| Amgen to Present at the Deutsche Bank 34th Annual Healthcare Conference |
13-May-2009 |
| Amgen Announces Voting Results Of Annual Meeting Of Stockholders |
6-May-2009 |
| Amgen and ONSEdge Partner With Cancer Survivor Jan Ping for New Campaign |
30-Apr-2009 |
| Photos: Amgen and ONSEdge Partner With Cancer Survivor Jan Ping for New Campaign |
30-Apr-2009 |
| Amgen's First Quarter 2009 Adjusted Earnings Per Share Decreased 4 Percent to $1.08 |
23-Apr-2009 |
| Amgen Announces Webcast of 2009 First Quarter Financial Results |
20-Apr-2009 |
| Amgen to Present at the Citigroup Biotech Day |
30-Mar-2009 |
| Amgen to Present at the Cowen and Company Annual Healthcare Conference |
16-Mar-2009 |
| Amgen to Present at the Barclays Capital Global Healthcare Conference |
9-Mar-2009 |
| "Project Runway's" Tim Gunn Launches Addressing Psoriasis(TM) Campaign to Advocate that Patients Shouldn't Let Psoriasis Impact Personal Style |
4-Mar-2009 |
| FDA Accepts Amgen's Submission and Files Biologics License Application for Denosumab |
18-Feb-2009 |
| Independent Data Monitoring Committee Recommends Resuming Enrollment of Non-Squamous NSCLC Patients in the Motesanib MONET1 Trial |
11-Feb-2009 |
| Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) |
6-Feb-2009 |
| Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 |
26-Jan-2009 |
| Amgen's Breakaway from Cancer Initiative Expands to Help Cancer Patients Access Broad Spectrum of Cancer Resources and Services |
22-Jan-2009 |
| Amgen Announces Webcast of 2008 Fourth Quarter and Full Year Financial Results |
20-Jan-2009 |
| Amgen to Present at the 27th Annual JP Morgan Healthcare Conference |
7-Jan-2009 |
| Amgen Submits Biologics License Application for FDA Approval of Denosumab in Women With Postmenopausal Osteoporosis and in Patients Undergoing Hormone Ablation for Either Prostate or Breast Cancer |
19-Dec-2008 |
| Oncology Biomarker KRAS to be Discussed at FDA Panel Meeting |
16-Dec-2008 |
| Long-term Follow Up Interim Data Show Nplate(TM) Increased and Sustained Platelet Counts in Adult Chronic ITP Patients |
8-Dec-2008 |
| Nplate(TM) (Romiplostim) Receives Positive Opinion for Marketing Authorisation in the European Union |
21-Nov-2008 |
| Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer |
19-Nov-2008 |
| Amgen Foundation Announces $2.5 Million Expansion of Amgen Scholars Program to Europe |
10-Nov-2008 |
| Amgen Positioned to Deliver Attractive Growth Over Next Five Years |
7-Nov-2008 |
| Amgen to Webcast 2008 Business Review Meeting on November 7 From Millennium Hotel in New York |
3-Nov-2008 |
| Call for Applications: The Amgen Award for Science Teaching Excellence |
3-Nov-2008 |
| Enbrel(R) (etanercept) Is the First Biologic With Published Efficacy and Safety Data for up to a Decade of Continuous Use for the Treatment of Moderate to Severe Rheumatoid Arthritis |
27-Oct-2008 |
| Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 |
22-Oct-2008 |
| Amgen Announces Webcast of 2008 Third Quarter Financial Results |
20-Oct-2008 |
| Amgen Issues Statement on Court of Appeals Ruling That Affirms Preliminary Injunction Against Roche |
10-Oct-2008 |
| Amgen Appoints Francois de Carbonnel to the Company's Board of Directors |
3-Oct-2008 |
| District Court Affirms Patent Infringement Rulings and Finds That Amgen is Entitled to a Permanent Injunction against Roche |
2-Oct-2008 |
| Amgen Receives Executive Summary from Independent Cochrane Collaboration Review of ESAs in Oncology |
30-Sep-2008 |
| Amgen to Present at UBS Global Life Sciences Conference |
22-Sep-2008 |
| Amgen to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medical Devices Conference |
16-Sep-2008 |
| Denosumab Osteoporosis Trial Finds Patients Transitioned from Alendronate (Fosamax(R)) to Denosumab Achieved Significantly Greater Gains in Bone Mineral Density versus Those Continuing on Alendronate |
15-Sep-2008 |
| Biovitrum to Acquire Kepivance(R) and Stemgen(R) and Exclusively License Kineret(R) from Amgen |
15-Sep-2008 |
| Amgen to Present Important Clinical Trial Data at Two Key Congresses |
11-Sep-2008 |
| Amgen to Present at the Morgan Stanley Global Healthcare Unplugged Conference |
8-Sep-2008 |
| Amgen and Wyeth Statement on the FDA Safety Announcement Regarding Tumor Necrosis Factor (TNF) Blockers |
4-Sep-2008 |
| FDA Approves Nplate(TM) for Long-Term Treatment of Adult Chronic ITP |
22-Aug-2008 |
| Amgen Licenses Molecule for the Treatment of Chronic and Neuropathic Pain to Ortho-McNeil-Janssen Pharmaceuticals, Inc. |
31-Jul-2008 |
| Amgen Issues Statement in Response to Revised ESA Labeling Received from the FDA Today |
30-Jul-2008 |
| Amgen's Second Quarter 2008 Adjusted Earnings Per Share Increased 2 Percent to $1.14 |
28-Jul-2008 |
| Amgen Announces Positive Top-Line Results for Denosumab Pivotal Postmenopausal Osteoporosis Trial |
25-Jul-2008 |
| 250 Amgen Scholars from 10 Premier Universities Convene for National Summer Symposium to Explore Drug Discovery & Development |
21-Jul-2008 |
| Amgen Announces Webcast of 2008 Second Quarter Financial Results |
17-Jul-2008 |
| Study Showed Half of Patients Treated with Enbrel(R) (etanercept) Plus Methotrexate Can Achieve DAS Clinical Remission and 80 Percent Had No Progression of Joint Damage in Active Early Rheumatoid Arthritis |
15-Jul-2008 |
| Amgen Announces Positive Top-Line Results for Denosumab Treatment of Bone Loss in Men With Non-Metastatic Prostate Cancer Undergoing Androgen Deprivation Therapy |
14-Jul-2008 |
| Amgen and Ortho Biotech Settle Antitrust Suit |
11-Jul-2008 |
| Amgen Commits to PhRMA's Enhanced Code on Interactions with Healthcare Professionals as Part of the Company's 'Clearly Amgen' Initiative |
10-Jul-2008 |
| New Data Show Preemptive Treatment May Significantly Reduce Skin Toxicities in Patients Receiving Vectibix(R) (Panitumumab) |
26-Jun-2008 |
| Amgen and Wyeth Statement on Outcome of Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) Meeting |
18-Jun-2008 |
| Enbrel(R) (etanercept) Application for the Treatment of Pediatric Psoriasis to be Discussed at FDA Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) Meeting |
18-Jun-2008 |
| Romiplostim Data Show Potential Long-Term Efficacy and Safety in Adults with Chronic ITP |
15-Jun-2008 |
| Amgen SVP of North American Commercial Operations James Daly to Present at the Goldman Sachs Healthcare Conference |
9-Jun-2008 |
| Amgen Names Anna Richo Senior Vice President of Worldwide Compliance |
6-Jun-2008 |
| 2008 Recipients of Amgen Award for Science Teaching Excellence Announced |
5-Jun-2008 |
| Amgen and Wyeth Statement on the FDA Early Communication About Tumor Necrosis Factor (TNF) Blockers |
4-Jun-2008 |
| Updated Data from Ongoing Phase 3 Trials Support the Continued Study of Vectibix(R) (panitumumab) in Combination with Standard Chemotherapy |
1-Jun-2008 |
| Amgen Reports Positive Data at ASCO from Three Studies of Denosumab in Cancer Patients |
31-May-2008 |
| Interim Phase 2 Results of Open-Label Clinical Trial of Denosumab in Giant Cell Tumor of Bone Demonstrated 87 Percent Response Rate |
31-May-2008 |
| Amgen Presents New Data at ASCO on Four Investigational Molecules from Oncology Pipeline |
31-May-2008 |
| Amgen to Webcast Investor Meeting at Upcoming American Society of Clinical Oncology Conference |
29-May-2008 |
| Denosumab Achieved Superior Bone Mineral Density Gains in Head-to-Head Trial Versus Weekly Alendronate (FOSAMAX(R)) |
28-May-2008 |
| Amgen Announces Webcast to Discuss Results of denosumab Phase 3 Head-to-Head Study versus alendronate at the Upcoming European Symposium on Calcified Tissues Conference |
27-May-2008 |
| Amgen Posts Medical Education and Foundation Grants and Donations as Part of the Company's 'Clearly Amgen' Initiative |
22-May-2008 |
| Denosumab Osteoporosis Study Meets Primary and All Secondary Bone Mineral Density Endpoints in Alendronate (FOSAMAX(R)) Transition Study |
19-May-2008 |
| Amgen Highlights Data to Be Presented at ASCO |
15-May-2008 |
| Amgen VP of Investor Relations Arvind Sood to Present at the Baird Growth Stock Conference |
13-May-2008 |
| Amgen Announces Voting Results of Annual Meeting of Stockholders |
7-May-2008 |
| Amgen to Participate in CHMP Oncology Scientific Advisory Group Meeting in May |
6-May-2008 |
| Amgen to Participate in Dermatologic and Ophthalmic Drugs Advisory Committee Meeting in June |
1-May-2008 |
| Amgen CFO Bob Bradway to Present at the Morgan Stanley Global Healthcare Unplugged Conference |
30-Apr-2008 |
| Amgen's First Quarter 2008 Adjusted Earnings Per Share Increased 4 percent to $1.12 |
24-Apr-2008 |
| Amgen Announces Webcast of 2008 First Quarter Financial Results |
16-Apr-2008 |
| Amgen Presents Preclinical and Clinical Data from Oncology Programs |
15-Apr-2008 |
| Amgen Scientist Visits Los Angeles Classroom During Teach For America Week |
14-Apr-2008 |
| Early Data on Amgen's Anti-Angiogenesis Pipeline Molecules Suggest Biologic Activity Across Tumor Types |
13-Apr-2008 |
| Amgen-Teach for America Summit to Focus on Strategies for Advancing Math and Science Education |
11-Apr-2008 |
| Amgen Statement on Romiplostim PDUFA Date |
8-Apr-2008 |
| Amgen's Oncology Pipeline Data Highlighted at Upcoming Scientific Meeting |
3-Apr-2008 |
| National Kidney Foundation Introduces Plan to Track Patients in National Screening Program |
3-Apr-2008 |
| Pivotal Phase 3 Data Show Denosumab Increased Bone Density at Multiple Skeletal Sites in Early and Later Stage Postmenopausal Women |
2-Apr-2008 |
| Amgen and Wyeth Announce Updates to U.S. Prescribing Information for Enbrel(R) |
17-Mar-2008 |
| Amgen to Present at the 28th Annual Cowen Healthcare Conference and the 11th Annual Lehman Brothers Global Healthcare Conference |
14-Mar-2008 |
| Amgen to Discuss Benefits and Risks of ESA Treatment for Cancer Patients with Anemia Due to Chemotherapy at FDA ODAC Meeting |
13-Mar-2008 |
| Amgen Statement on Successful Outcome of Romiplostim Panel Meeting |
12-Mar-2008 |
| Amgen to Discuss Romiplostim Application at FDA ODAC Meeting |
12-Mar-2008 |
| Amgen Announces Update to U.S. Prescribing Information for Aranesp(R) and EPOGEN(R) |
7-Mar-2008 |
| Kyowa Hakko and Amgen Enter Licensing Agreement for Anti-CCR4 Humanized Monoclonal Antibody |
5-Mar-2008 |
| The Colon Cancer Alliance Teams up with Joan Lunden for Amgen Sponsored Workshop Series Designed to Provide Support to Patients and Caregivers |
5-Mar-2008 |
| EU Commission Approves Updated Prescribing Information for Aranesp(R) |
5-Mar-2008 |
| KRAS Biomarker Analysis from Pivotal Vectibix(TM) Trial Published |
4-Mar-2008 |
| Amgen and Takeda Announce Exclusive Collaboration in Japan on up to 13 Amgen Clinical Candidates |
4-Feb-2008 |
| New Findings Show Enbrel(R) (etanercept) Significantly Reduced Levels of C-Reactive Protein, a Marker of Inflammation, in Patients with Moderate to Severe Plaque Psoriasis |
1-Feb-2008 |
| Pooled Phase 3 Study of Nplate(TM) (Romiplostim) in Adult Patients with Chronic ITP Published in The Lancet |
31-Jan-2008 |
| Amgen Statement on Aranesp Manuscript in the Journal of Clinical Oncology |
28-Jan-2008 |
| Interim Safety Data Presented on Vectibix(TM) (Panitumumab) in Combination with Standard Chemotherapy |
27-Jan-2008 |
| Denosumab Osteoporosis Study Met Primary and All Secondary Bone Mineral Density Endpoints in a Head-to-Head Comparison with Weekly Alendronate (FOSAMAX(R)) |
24-Jan-2008 |
| Amgen's Fourth Quarter 2007 Adjusted Earnings Per Share (EPS) Increased 11 Percent to $1.00; Full Year 2007 Adjusted EPS Increased 10 Percent to $4.29 |
24-Jan-2008 |
| KRAS Gene Status May Impact Vectibix(TM) (Panitumumab) Efficacy and Patient Reported Outcomes in Advanced Colorectal Cancer Patients |
24-Jan-2008 |
| Amgen Commences Registered Exchange Offer for Its Senior Floating Rate Notes Due 2008, 5.85 Percent Senior Notes Due 2017 and 6.375 Percent Senior Notes Due 2037 |
17-Jan-2008 |
| New Study Reports Enbrel(R) (Etanercept) Significantly Improved Moderate to Severe Plaque Psoriasis in Children and Adolescents |
16-Jan-2008 |
| Amgen Announces Webcast of 2007 Fourth Quarter and Full Year Financial Results |
16-Jan-2008 |
| Breakaway from Cancer Public Service Announcement Spreads Support and Hope |
10-Jan-2008 |
| Amgen Updates 2007 Adjusted EPS Guidance and Outlines 2008 Expense Outlook at the JP Morgan Healthcare Conference |
8-Jan-2008 |
| Amgen to Present at the 26th Annual JP Morgan Healthcare Conference |
4-Jan-2008 |
| Pivotal Phase 3 Data Show Denosumab Increased Bone Density Throughout Skeleton in Non-Metastatic Breast Cancer Patients on Adjuvant Aromatase Inhibitor Therapy |
14-Dec-2007 |
| Pivotal Phase 3 Nplate(TM) Study in Non-Splenectomized Patients Met Primary Endpoints |
10-Dec-2007 |
| Pivotal Phase 3 Romiplostim Study in Splenectomized Patients Meets Primary Endpoints |
8-Dec-2007 |
| Amgen in Discussions with FDA to Update U.S. Prescribing Information for ESAs |
6-Dec-2007 |
| Vectibix(R) Approved in the European Union for the Treatment of Metastatic Colorectal Cancer |
5-Dec-2007 |
| Amgen Foundation and Leading Universities Invite College Students to Apply for Amgen Scholars Program |
4-Dec-2007 |
| Amgen Announces Interim Results of Aranesp(R) ''PREPARE'' Study in Breast Cancer Patients |
30-Nov-2007 |
| Amgen Announces ``My Cancer Coach'' Contest Winners at the College Hoops Classic |
15-Nov-2007 |
| Amgen to Provide New Evidence as Part of a Formal Reconsideration of CMS' National Coverage Determination on ESAs |
8-Nov-2007 |
| Amgen Announces Updates to the U.S. Prescribing Information for ESAs |
8-Nov-2007 |
| New Data Show That Half of Patients with Active Early Rheumatoid Arthritis Achieved Clinical Remission at One Year When Treated with Enbrel(R) (etanercept) Plus Methotrexate |
7-Nov-2007 |
| Call for Applications: The Amgen Award for Science Teaching Excellence |
1-Nov-2007 |
| Amgen Foundation Donates $500,000 To Aid In Southern California Wildfire Relief Efforts |
25-Oct-2007 |
| Amgen's Third Quarter 2007 Adjusted Earnings Per Share Increased 4 Percent to $1.08 |
24-Oct-2007 |
| Jury Rules Roche Infringes Amgen's EPO Patents |
23-Oct-2007 |
| Amgen Announces Webcast of 2007 Third Quarter Financial Results |
16-Oct-2007 |
| Amgen and Dompe Biotec to Combine Commercial Operations in Italy |
4-Oct-2007 |
| Amgen to Postpone Indefinitely Its Plans for a Manufacturing Facility in Ireland |
3-Oct-2007 |
| Amgen Appoints Vance D. Coffman to the Company's Board of Directors |
2-Oct-2007 |
| Amgen Provides Update on Late-Stage and Early-Stage Pipeline at UBS Global Life Sciences Conference |
28-Sep-2007 |
| Aranesp(R) (darbepoetin alfa) Approved for Use in All European Paediatric Patients with Chronic Renal Failure Anaemia |
28-Sep-2007 |
| Amgen Receives Proposal for Amending EU Prescribing Information for Aranesp(R) |
27-Sep-2007 |
| Phase 2 Study Suggests That Extended Dosing of Aranesp(R) is as Efficacious as Weekly Dosing |
26-Sep-2007 |
| New Analysis Suggests First Cycle Use of Neulasta(R) Reduces Febrile Neutropenia Hospitalizations and Chemotherapy Dose Reductions in Breast Cancer Patients Compared to Current Practice |
26-Sep-2007 |
| New Biomarker Data Links KRAS Gene to Vectibix(TM) Clinical Response |
25-Sep-2007 |
| Aranesp(R) DAHANCA 10 Study Results Presented at ECCO Annual Meeting |
25-Sep-2007 |
| Vectibix(TM) (panitumumab) Receives Positive Opinion for Marketing Authorization in the European Union |
21-Sep-2007 |
| Amgen Oncology Highlights Upcoming Data Presentations at the 2007 European Conference on Clinical Oncology |
21-Sep-2007 |
| Amgen to Review Benefits, Risks of ESA Therapy in Chronic Renal Failure Patients at FDA Advisory Committee |
11-Sep-2007 |
| Aranesp(R) Study Showing No Negative Impact on Survival in SCLC Presented at World Conference on Lung Cancer |
6-Sep-2007 |
| Amgen Foundation Awards Grant to Mentor LA to Help Improve Public High School Education in Los Angeles |
5-Sep-2007 |
| Court Rules That Roche Infringes One of Amgen's Erythropoietin Patents |
28-Aug-2007 |
| Amgen Restructures Due to Lower Aranesp(R) Revenues While Continuing to Invest in Innovation and Future Growth |
15-Aug-2007 |
| Amgen to Hold Conference Call Today after the Close of Financial Markets |
15-Aug-2007 |
| First Year Amgen Scholars and Leading Scientists Attend Symposium to Explore Drug Discovery & Development |
7-Aug-2007 |
| Dennis Fenton, Executive Vice President of Operations, Elects to Retire after 25 Years with Amgen |
1-Aug-2007 |
| Amgen Responds to Final CMS National Coverage Determination on Use of Erythropoiesis-Stimulating Agents in Oncology |
31-Jul-2007 |
| Amgen's Second Quarter 2007 Adjusted Earnings Per Share Increased 7 Percent to $1.12 |
26-Jul-2007 |
| Amgen Completes Acquisition of Ilypsa |
18-Jul-2007 |
| Amgen Completes Acquisition of Alantos |
16-Jul-2007 |
| Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program |
12-Jul-2007 |
| Amgen and Daiichi Sankyo Announce Agreement for Denosumab in Japan |
11-Jul-2007 |
| Amgen Announces Webcast of 2007 Second Quarter Financial Results |
11-Jul-2007 |
| Ralph Lauren Center for Cancer Care and Prevention Receives $2.5 Million from the Amgen Foundation to Launch National Patient Navigation Training Institute |
28-Jun-2007 |
| Amgen Submits Testimony to House Ways & Means Committee |
26-Jun-2007 |
| ENBREL Safety Data for up to Eight Years in Patients with Juvenile Rheumatoid Arthritis Being Presented at EULAR |
13-Jun-2007 |
| Amgen to Acquire Alantos Pharmaceuticals, a Private Biotechnology Company in Cambridge, Massachusetts |
6-Jun-2007 |
| Amgen to Acquire Ilypsa, a Private San Francisco Bay Area Biotechnology Company Focused on Kidney Disease Care |
4-Jun-2007 |
| Amgen Submits Comments in Response to CMS' Proposed National Coverage Decision |
2-Jun-2007 |
| Amgen Oncology Highlights Upcoming Data Presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting |
29-May-2007 |
| Amgen to Appeal CHMP Opinion on Vectibix(TM) (Panitumumab) |
25-May-2007 |
| Amgen Prices $4 Billion of Senior Notes in Three Series; Company to Purchase Approximately $3 Billion in Common Stock |
24-May-2007 |
| Amgen to Offer $4 Billion in Three Series of Senior Notes; Company to Purchase Approximately $3 Billion in Common Stock |
23-May-2007 |
| Amgen Names David Lacey, M.D., Senior Vice President, Head of Research |
22-May-2007 |
| Amgen Recommends Rejection of Mini-Tender Offer by TRC Capital Corporation |
18-May-2007 |
| Amgen Announces Voting Results of Annual Meeting of Stockholders |
9-May-2007 |
| Final Vectibix(TM) Positive Pivotal Phase 3 Trial Results In Metastatic Colorectal Cancer Patients Published |
30-Apr-2007 |
| Amgen's First Quarter 2007 Revenue Increased 15 Percent to $3.7 Billion |
23-Apr-2007 |
| Aranesp(R) ``145 Study'' Shows No Difference in Survival in Patients with Small-Cell Lung Cancer |
19-Apr-2007 |
| 2007 Recipients of Amgen Award for Science Teaching Excellence Announced |
18-Apr-2007 |
| Aranesp(R) Phase 3 Study in Patients with Active Cancer Not Receiving Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual Meeting |
16-Apr-2007 |
| Amgen Announces Webcast of 2007 First Quarter Financial Results |
11-Apr-2007 |
| Amgen Names Robert Bradway Executive Vice President and Chief Financial Officer |
10-Apr-2007 |
| Amgen Discontinues Vectibix(TM) Treatment In PACCE Trial Evaluating Vectibix(TM) As Part Of Triple Combination Regimen |
22-Mar-2007 |
| Amgen to Present at the Lehman Brothers Tenth Annual Global Healthcare Conference |
19-Mar-2007 |
| Amgen to Present at the 27th Annual Cowen & Company Health Care Conference |
12-Mar-2007 |
| Amgen Announces Update To U.S. Prescribing Information for Aranesp(R) and EPOGEN(R) |
9-Mar-2007 |
| Prime Minister Tony Blair Opens Major Amgen Development Centre in London |
2-Mar-2007 |
| Amgen to Participate in Oncologic Drugs Advisory Committee in May |
28-Feb-2007 |
| Amgen to Participate in Goldman Sachs 'In Your Office' Call |
28-Feb-2007 |
| Amgen to Hold Analyst Call to Discuss Danish Head and Neck Cancer (DAHANCA) 10 Study |
16-Feb-2007 |
| Amgen Announces Proposals to Declassify Board to Be Presented at 2007 Annual Meeting and Adopts Majority Vote Bylaw |
15-Feb-2007 |
| Amgen CEO Kevin Sharer to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference |
6-Feb-2007 |
| Survey Indicates People with Chronic Moderate to Severe Plaque Psoriasis May Be Under-Treated |
2-Feb-2007 |
| Amgen Announces Put Option for Liquid Yield Option Notes Due 2032 and Zero Coupon Convertible Notes Due 2032 |
31-Jan-2007 |
| Amgen's Fourth Quarter 2006 Revenue Increased 17% to $3.8 Billion; Full Year 2006 Revenue Increased 15% to $14.3 Billion |
25-Jan-2007 |
| Amgen Launches 2007 Breakaway from Cancer Initiative |
16-Jan-2007 |
| Amgen Announces Webcast of 2006 Fourth Quarter and Full Year Financial Results |
11-Jan-2007 |
| Cytokinetics and Amgen Announce Strategic Alliance in Heart Failure |
3-Jan-2007 |
| Amgen Announces $5 Billion Stock Repurchase Plan |
13-Dec-2006 |
| Updated Interim Long-Term Follow-up Data Reported AMG 531 Dosed Once Weekly Increased and Sustained Platelet Counts in Patients with Immune Platelet Disorder |
11-Dec-2006 |
| Final Phase 2 Data Continue to Show Promising Results after One Year of Aranesp(R) Treatment for Anemia in Patients with Myelodysplastic Syndromes (MDS) |
10-Dec-2006 |
| Data Show Efficacy of Extended Dosing of Aranesp(R) in the Treatment of Chemotherapy-Induced Anemia |
9-Dec-2006 |
| New Phase 2 Data Show Promise of Aranesp(R) Treatment for Anemia of Cancer |
9-Dec-2006 |
| Amgen Submits Testimony to House Ways & Means Committee |
6-Dec-2006 |
| Amgen Responds to Reports About Use and Safety of EPOGEN and Aranesp in CKD Anemia Therapy |
4-Dec-2006 |
| Amgen Names Yuji Orihara President, Amgen KK |
1-Dec-2006 |
| Colorectal Patients Offered New Resource to Help Navigate Treatment Process |
29-Nov-2006 |
| District Court Judge Denies Preliminary Injunction in Ortho v. Amgen Suit |
22-Nov-2006 |
| Fashion Designer and Cancer Survivor Carmen Marc Valvo Offers Support |
20-Nov-2006 |
| Amgen Launches ChemoCoach.com and ``My Cancer Coach'' Contest in Conjunction with Sponsorship of College Hoops Classic Benefiting Coaches vs. Cancer |
16-Nov-2006 |
| Data Shows ENBREL Provides Sustained Clinical Improvements for People with Ankylosing Spondylitis for up to Three Years |
13-Nov-2006 |
| ENBREL is the First Biologic to Publish Data Showing Safety and Sustained Efficacy for up to Nine Years in Patients with Moderate-to-Severe Rheumatoid Arthritis |
12-Nov-2006 |
| AMG 706 Shows Activity in Phase 2 Study of Patients with Advanced Imatinib-Resistant Gastrointestinal Stromal Tumors |
4-Nov-2006 |
| Nominations Open for the Amgen Award for Science Teaching Excellence |
2-Nov-2006 |
| Amgen Completes Acquisition of Avidia |
24-Oct-2006 |
| Amgen's Third Quarter 2006 Adjusted Earnings Per Share, Excluding Stock Option Expense, Increased 22 Percent to $1.04 |
23-Oct-2006 |
| U.S. District Court Denies Roche Motion to Dismiss Amgen Patent Infringement Lawsuit |
20-Oct-2006 |
| Amgen Foundation Launches $25 Million Undergraduate Research Program |
19-Oct-2006 |
| Amgen Receives Complete Response Letter for Extended Dosing of Aranesp(R) for Patients with Chronic Kidney Disease and Anemia |
13-Oct-2006 |
| Amgen Announces Webcast of Third Quarter Financial Results |
9-Oct-2006 |
| Amgen to Acquire Avidia, a Privately Held Biopharmaceutical Company in the San Francisco Bay Area |
29-Sep-2006 |
| Amgen Introduces Comprehensive Financial Assistance Programs for Cancer Patients |
27-Sep-2006 |
| FDA Approves Vectibix(TM) to Treat Patients with Metastatic Colorectal Cancer |
27-Sep-2006 |
| Amgen Names Thomas Flanagan Senior Vice President and Chief Information Officer |
20-Sep-2006 |
| Amgen Announces License Agreement with Yeda Research and Development Company Ltd.; License Agreement Accords Amgen Freedom to Operate Under '866 Patent |
19-Sep-2006 |
| Amgen Presents Denosumab and Sclerostin Antibody Data at American Society for Bone and Mineral Research Annual Meeting; Data Suggest the Potential for Targeting the Key Proteins, RANK Ligand and Sclerostin, for Bone Loss Conditions |
19-Sep-2006 |
| Amgen Launches Aranesp(R) (Darbepoetin Alfa) Prefilled SureClick(TM) Autoinjector for Treatment of Anemia Associated with Chemotherapy and Chronic Kidney Disease |
7-Sep-2006 |
| Amgen Wins TKT Appeal |
3-Aug-2006 |
| Amgen's Second Quarter 2006 Adjusted Earnings Per Share, Excluding Stock Option Expense, Increased 19 Percent to $1.05; GAAP Earnings Per Share of 1 Cent Reflects $1.1 Billion One-Time Write-Off of In-Process R&D Related to Abgenix Acquisition |
20-Jul-2006 |
| Amgen Update on Presentation Materials for Webcast of Second Quarter Financial Results |
18-Jul-2006 |
| Amgen Announces EVOLVE Trial(TM) To Investigate Impact of Sensipar(R)/Mimpara(R) (cinacalcet HCl) on Mortality and Cardiovascular Morbidity in Secondary Hyperparathyroidism Patients With Chronic Kidney Disease Receiving Dialysis |
16-Jul-2006 |
| ITC Judge Grants Summary Determination That Roche's Activities Are Covered by Clinical Trial Exemption |
7-Jul-2006 |
| Amgen Announces Webcast of Second Quarter Financial Results |
6-Jul-2006 |
| Final Results of Phase 2 Clinical Trial Program Suggest Treatment of Anemia with Aranesp(R) (Darbepoetin Alfa) May Decrease Risk of Hospitalization and All-Cause Mortality in Heart Failure Patients with Anemia, Based on a Prespecified Pooled Analysis |
19-Jun-2006 |
| FDA Grants Priority Review of Panitumumab for Treatment of Patients with Metastatic Colorectal Cancer |
12-Jun-2006 |
| Phase 2 Interim Data Show Denosumab Decreased Bone Turnover in Advanced Cancer Patients with Bone Metastases |
4-Jun-2006 |
| Interim Data Suggest Potential Benefits of Aranesp(R) Dosed Every Three Weeks with Intravenous Iron for Chemotherapy-Induced Anemia; 94 Percent of Patients Achieved Target Hemoglobin Level |
3-Jun-2006 |
| Interim Phase 2 Aranesp(R) Data Suggest Major Response after 27/28 Weeks of Treatment for Anemia in Patients with Myelodysplastic Syndromes (MDS) |
3-Jun-2006 |
| New Interim Phase 2 Data Suggest the Antitumor Activity of Panitumumab in Metastatic Colorectal Cancer |
3-Jun-2006 |
| Amgen Oncology Highlights Upcoming Data Presentations at the American Society of Clinical Oncology Annual Meeting; Clinical Data to be Presented on Four Investigational Targeted Cancer Therapies |
31-May-2006 |
| Large Head-to-Head Study of Aranesp(R) Dosed Every Two Weeks versus Epoetin Alfa Dosed Weekly Published in the Journal of Clinical Oncology |
18-May-2006 |
| ITC Accepts Amgen's Complaint to Investigate Roche's Importation of Peg-EPO |
9-May-2006 |
| Alcon and Amgen Sign Collaboration Agreement to Develop and Commercialize Innovative Therapies in Ophthalmology |
24-Apr-2006 |
| Amgen's First Quarter 2006 Adjusted Earnings Per Share, Excluding Stock Option Expense, Increased 26 Percent to 91 Cents; First Quarter 2006 GAAP Earnings Per Share Increased 22 Percent to 82 Cents |
18-Apr-2006 |
| Amgen Files with ITC Against Roche's Importation of peg-EPO |
11-Apr-2006 |
| Amgen Announces Webcast of First Quarter Financial Results |
4-Apr-2006 |
| Randomized Phase 3 Trial Shows Panitumumab Significantly Improved Progression-Free Survival and Disease Control in Metastatic Colorectal Cancer Patients |
3-Apr-2006 |
| Amgen Completes Acquisition of Abgenix; Acquisition Provides Amgen with Full Ownership of Panitumumab and Eliminates a Denosumab Royalty |
3-Apr-2006 |
| Amgen and Abgenix Complete Biologics License Application for FDA Approval of Panitumumab |
30-Mar-2006 |
| FDA Approves Extended Dosing of Aranesp(R) to Treat Chemotherapy-Induced Anemia; Every-Three-Week Dosing Can Provide Added Convenience, Potentially Reducing Number of Clinic Visits and Injections for Anemia Treatment |
27-Mar-2006 |
| New Phase 2 Data Suggest Treatment of Anemia with Aranesp(R) (Darbepoetin Alfa) May Provide Clinical Benefits in Heart Failure Patients |
13-Mar-2006 |
| Hundreds of Local Residents Participate in Breakaway from Cancer Charity Ride to Benefit The Wellness Community; Bruce Jenner Kicks-off Twenty-Five Mile Ride That Coincides with Stage Six of Amgen Tour of California |
25-Feb-2006 |
| Investigational Therapy Denosumab Increased Bone Mineral Density with Twice-Yearly Dosing; One Year Data Published in New England Journal of Medicine |
22-Feb-2006 |
| Amgen Prices $5.0 Billion Convertible Senior Notes; Company to Purchase Approximately $3.0 Billion in Common Stock |
14-Feb-2006 |
| Amgen to Offer $4.0 Billion Convertible Senior Notes; Company to Purchase Approximately $3.0 Billion in Common Stock |
13-Feb-2006 |
| Amgen and Biovitrum Expand Existing License Agreement for Innovative Treatment of Type 2 Diabetes and Other Metabolic Disorders |
13-Feb-2006 |
| Amgen Continues Manufacturing Expansion with Additional $1 Billion Investment in Puerto Rico |
2-Feb-2006 |
| Amgen's Fourth Quarter 2005 Adjusted Earnings Per Share Increased 29 Percent to 75 Cents; Full Year 2005 Adjusted Earnings Per Share Increased 33 Percent to $3.20 |
26-Jan-2006 |
| Amgen Announces Webcast of 2005 Fourth Quarter and Full Year Financial Results |
9-Jan-2006 |
| Amgen to Acquire Abgenix for $22.50 Per Share; Provides Amgen With Full Ownership of Panitumumab and Eliminates a Denosumab Royalty |
14-Dec-2005 |
| New Phase 3 Data Show Potential Benefits of Aranesp(R) Dosed Every Three Weeks for Chemotherapy-Induced Anemia; Aranesp Treatment Achieved and Maintained Target Hemoglobin Levels and Reduced Incidence of Red Blood Cell Transfusions |
12-Dec-2005 |
| Interim Long-Term Follow-up Data Show AMG 531 Increases Platelets in Patients with Immune Thrombocytopenic Purpura; Results Suggest Once-Weekly Dosing of AMG 531 Results in Sustained Platelet Response |
12-Dec-2005 |
| Updated Interim Aranesp(R) Phase 2 Data Suggest Major Response in Anemic Patients with Myelodysplastic Syndrome (MDS); Patients with Bone Marrow Disorder Also Showed Improvements in Hemoglobin Levels and Fatigue |
11-Dec-2005 |
| The Wellness Community and Amgen Partner with Professional Cyclist George Hincapie to Launch 'Breakaway from Cancer' Initiative |
8-Dec-2005 |
| Amgen Announces $5 Billion Stock Repurchase Plan |
7-Dec-2005 |
| Amgen Foundation Donates $500,000 to South Asia Earthquake Relief Efforts |
15-Nov-2005 |
| Two-Year Trial Results of Amgen Investigational Therapy for Bone Loss, Denosumab, Show Increased Bone Mineral Density with Twice-Yearly Dosing |
13-Nov-2005 |
| Treatment Has Demonstrated Improvement in Physical Function and Kept Joint Damage from Progressing at Three Years |
13-Nov-2005 |
| Data Show Aranesp(R) (Darbepoetin Alfa) Administered Once Monthly Maintains Hemoglobin Levels in Chronic Kidney Disease Patients with Anemia |
12-Nov-2005 |
| Nominations Open for the Amgen Award for Science Teaching Excellence; 19 Outstanding Teachers Will Be Recognized in Communities Where Amgen Operates |
10-Nov-2005 |
| Amgen Files Lawsuit Against Roche for Patent Infringement |
9-Nov-2005 |
| Panitumumab Significantly Improves Progression-Free Survival in Phase 3 Randomized Metastatic Colorectal Cancer Study |
3-Nov-2005 |
| Media Notification/Webcast Notification - Amgen and Abgenix to Conduct Conference Call and Webcast Regarding Panitumumab Pivotal Study Results - November 3, 2005, 8:00 am PT |
3-Nov-2005 |
| Amgen Announces Sponsorship of World-Class Cycling Event; Company to Join with the Wellness Community to Raise Awareness and Funds to Help People Fight Cancer |
2-Nov-2005 |
| European Commission Approves Kepivance(TM) (Palifermin) for Oral Mucositis in Cancer Patients Undergoing Blood and Bone Marrow Transplant |
28-Oct-2005 |
| Amgen's Third Quarter 2005 Adjusted Earnings Per Share Increased 33 Percent to 85 Cents; Third Quarter 2005 GAAP Earnings Per Share Increased to 77 Cents from 18 Cents |
19-Oct-2005 |
| Amgen Announces Webcast of Third Quarter Financial Results |
3-Oct-2005 |
| FDA Expands Neulasta(R) Label; New Label Extends First-Cycle Protection From Infection To Cancer Patients Receiving Moderately Myelosuppressive Chemotherapy |
15-Sep-2005 |
| Amgen Announces FDA Licensure of Two New Manufacturing Facilities; Company Continues to Meet Increased Demand for Its Novel Therapeutics |
6-Sep-2005 |
| Amgen Names Phyllis Piano Vice President, Corporate Communications and Philanthropy |
2-Sep-2005 |
| Amgen Announces Initiation of Phase 3 Trial to Evaluate the Impact of Treating Anemia with Darbepoetin Alfa in Patients with Heart Failure to Reduce Mortality and Hospitalization |
2-Sep-2005 |
| Amgen Donates $2.5 Million to Hurricane Katrina Relief Efforts |
1-Sep-2005 |
| Amgen Names Michael Kelly as Chief Accounting Officer |
10-Aug-2005 |
| Amgen Adopts ``Guiding Principles'' for Direct-to-Consumer Advertising |
2-Aug-2005 |
| Abgenix and Amgen Announce FDA Grants Panitumumab Fast Track Designation for Metastatic Colorectal Cancer |
1-Aug-2005 |
| Kepivance(TM) (palifermin) Receives Positive Regulatory Opinion for Approval in Europe |
28-Jul-2005 |
| Amgen's Second Quarter 2005 Adjusted Earnings Per Share Increased 42 Percent to 88 Cents |
19-Jul-2005 |
| Interim Data Suggest Major Response with Aranesp(R) in Anemic Patients with Myelodysplastic Syndromes (MDS) |
6-Jul-2005 |
| Amgen Announces Webcast of Second Quarter Financial Results |
23-Jun-2005 |
| FDA Expands ENBREL Psoriatic Arthritis Indication -- ENBREL Approved as First and Only Treatment to Improve Physical Function in These Patients |
1-Jun-2005 |
| 2005 Recipients of Amgen Award for Science Teaching Excellence Announced; 19 Outstanding Science Teachers and Their Schools Recognized in Communities Across U.S. and Puerto Rico |
19-May-2005 |
| Amgen Names Jim Daly, Senior Vice President, North America Commercial Operations |
17-May-2005 |
| Further Phase 2 Data Confirm Panitumumab Single-Agent Antitumor Activity in Patients with Metastatic Colorectal Cancer |
17-May-2005 |
| Aranesp Dosed Every Three Weeks Achieved and Maintained Target Hemoglobin Levels in Patients with Chemotherapy-Induced Anemia |
15-May-2005 |
| Final Results of Phase 3 Head-to-Head Study Demonstrate Aranesp Dosed Every Two Weeks is Comparable to Epoetin Alfa Dosed Weekly in Cancer Patients with Chemotherapy-Induced Anemia |
15-May-2005 |
| Large Community-Based Clinical Trial in Older Cancer Patients Suggests Benefits of Neulasta in First and Subsequent Cycles Of Chemotherapy |
15-May-2005 |
| Amgen Submits Supplemental Biologics License Application for Aranesp Extended Dosing; Phase 3 Study Evaluated Aranesp Dosed Once Every Three Weeks in Patients with Chemotherapy-Induced Anemia |
6-May-2005 |
| Amgen Announces Expiration and Results of its Exchange Offer for Its Outstanding Liquid Yield Option Notes Due 2032 |
5-May-2005 |
| Amgen Announces One-Day Extension of Its Exchange Offer for Its Outstanding Liquid Yield Option Notes Due 2032 |
4-May-2005 |
| Amgen Announces Plans to Webcast Selected Management Presentations |
3-May-2005 |
| Phase 3 Clinical Trial Initiated to Evaluate the Use of Panitumumab Therapy for First-Line Treatment of Metastatic Colorectal Cancer; Study Evaluates Panitumumab Administered With Bevacizumab and Chemotherapy |
26-Apr-2005 |
| Amgen's First Quarter 2005 Adjusted Earnings Per Share Increased 26 Percent to 72 Cents |
21-Apr-2005 |
| Multimedia Available: Landmark Trial to Link Reduction in Cardiovascular Risk With Treatment of Anemia in Diabetics With Chronic Kidney Disease |
11-Apr-2005 |
| Amgen Commences Exchange Offer for Its Outstanding Liquid Yield Option Notes Due 2032 |
6-Apr-2005 |
| Amgen Announces Webcast of First Quarter Financial Results |
4-Apr-2005 |
| Landmark Trial Will Evaluate the Impact of Treating Anemia on Cardiovascular Outcomes in Patients with Chronic Kidney Disease and Type 2 Diabetes |
28-Mar-2005 |
| Amgen Announces Results of Its Repurchase of Tendered Liquid Yield Option Notes Due 2032 |
2-Mar-2005 |
| Phase 3 Study Published in The Journal of Clinical Oncology Shows First-Cycle Administration of Neulasta Significantly Lowers Incidence of Neutropenia with Related Fever and Hospitalization |
25-Feb-2005 |
| Amgen Announces One-Time Cash Payment and Additional Put Right for Liquid Yield Option Notes Due 2032 |
22-Feb-2005 |
| Treatment with ENBREL Had a Positive Effect on Activities of Daily Living for Patients with Psoriasis |
18-Feb-2005 |
| Following Complete Review of Phase 2 Trial Data Amgen Confirms Decision to Halt GDNF Study; Comprehensive Review of Scientific Findings, Patient Safety, Drove Decision |
11-Feb-2005 |
| Amgen Announces Put Option Notification for Liquid Yield Option Notes Due 2032 |
31-Jan-2005 |
| Amgen's Fourth Quarter 2004 Adjusted Earnings Per Share Increased 26 Percent to 58 Cents; Full Year 2004 Adjusted Earnings Per Share Increased 26 Percent to $2.40 |
27-Jan-2005 |
| Amgen Announces Webcast of 2004 Fourth Quarter and Full Year Financial Results |
21-Jan-2005 |
| Amgen Significantly Expands Support of Patient Assistance Programs; Financial Support To Help Ensure Patients Have Access To Innovative Therapies Critical To Care |
11-Jan-2005 |
| Amgen Donates $1 Million and Establishes Tsunami Relief Program; Staff Donations, Company Contributions To Help South Asia Victims |
3-Jan-2005 |
| FDA Approves Kepivance for Severe Oral Mucositis in Cancer Patients Undergoing Bone Marrow Transplant; Pivotal Phase 3 Study Published in This Week's New England Journal of Medicine |
15-Dec-2004 |
| Amgen Names Willard Dere Senior Vice President, Global Development |
14-Dec-2004 |
| Randomized Head-to-Head Trial Shows Aranesp Dosed Every Two Weeks is Comparable to Epoetin Alfa Dosed Once a Week in Breast Cancer Patients |
11-Dec-2004 |
| Phase 3 Study Shows Majority of Neutropenia with Related Fever and Hospitalization Occurs in First Treatment Cycle for Breast Cancer Patients Not Receiving Neulasta |
10-Dec-2004 |
| Amgen Announces $5 Billion Stock Repurchase Plan |
7-Dec-2004 |
| FDA Grants Fast Track Designation for Amgen's AMG 531 and AMG 706 Experimental Therapies to Potentially Treat Life-Threatening Conditions |
6-Dec-2004 |
| Nominations Open for the Amgen Award For Science Teaching Excellence; 19 Outstanding Teachers Will Be Recognized in Communities Where Amgen Operates |
29-Nov-2004 |
| Nominations Open for the Amgen Award For Science Teaching Excellence |
29-Nov-2004 |
| Published Head-to-Head Data Show Aranesp Dosed Every Two Weeks is Comparable to Epoetin Alfa Dosed Once-a-Week |
24-Nov-2004 |
| Amgen Announces Offer of $2 Billion in Two Series of Senior Notes |
15-Nov-2004 |
| Amgen Announces the Formation of Amgen Ventures; Venture Capital Fund Designed to Provide Resources to Help Advance Early-Stage Biotechnology Companies and Human Therapeutics |
11-Nov-2004 |
| Amgen Launches Landmark Trial to Evaluate the Impact of Treating Anemia on Cardiovascular Risks in Patients with Chronic Kidney Disease and Type 2 Diabetes |
1-Nov-2004 |
| Interim Phase 2 Data Suggest Activity of Panitumumab with Chemotherapy in First-Line Treatment of Metastatic Colorectal Cancer |
1-Nov-2004 |
| European Commission Approves Innovative First-in-Class Treatment for a Serious Complication of Chronic Kidney Disease |
28-Oct-2004 |
| Amgen's Third Quarter 2004 Adjusted Earnings Per Share Increased 21 Percent to 64 Cents |
20-Oct-2004 |
| New Two-Year Data Show That Most Rheumatoid Arthritis Patients Treated with ENBREL Plus Methotrexate Had No Progression of Joint Damage |
18-Oct-2004 |
| Court Rules in Amgen's Favor in TKT Litigation; Affirms Validity of EPO Patents |
15-Oct-2004 |
| Amgen Names Rolf Hoffmann Senior Vice President, European Operations |
13-Oct-2004 |
| Amgen Announces Webcast of Third Quarter Financial Results |
12-Oct-2004 |
| Amgen Investigational Therapy for Bone Loss, AMG 162, Increased Bone Mineral Density with Twice Yearly Injection |
3-Oct-2004 |
| FDA Approves ENBREL to Induce Major Clinical Response in Patients With Rheumatoid Arthritis; Additional Data Demonstrates Increased Levels of Sustained Disease Control |
28-Sep-2004 |
| FDA Approves New and Easy Way to Take ENBREL; Benefits of ENBREL Delivered in Convenient Once-Weekly 50 mg/mL Prefilled Syringe |
28-Sep-2004 |
| Amgen Announces Plans to Webcast Selected Management Presentations |
27-Sep-2004 |
| Aranesp Approved for Extended Dosing by European Commission |
21-Sep-2004 |
| Amgen Names Arvind Sood Vice President, Investor Relations |
16-Sep-2004 |
| Amgen Completes Acquisition of Tularik; Acquisition Enhances Amgen's Strong Research Organization and Establishes Amgen in the San Francisco Bay Area |
13-Aug-2004 |
| First Patients Dosed with Amgen's AMG 162 In Phase 3 Studies for Postmenopausal Osteoporosis and Treatment-Induced Bone Loss |
10-Aug-2004 |
| Aranesp Receives Positive Regulatory Opinion for Extended Dosing in Europe |
6-Aug-2004 |
| Mimpara -- Cinacalcet HCl -- Receives Positive Regulatory Opinion for Approval in Europe |
30-Jul-2004 |
| Lifestyle Coaching Program Launched Today Helps People with Rheumatoid Arthritis Remain Active |
26-Jul-2004 |
| Amgen's Second Quarter 2004 Total Product Sales, Adjusted Earnings and GAAP Earnings Per Share Increased 27 Percent |
22-Jul-2004 |
| Amgen Names Brian Kotzin Vice President, Inflammation Clinical Development and Willard Dere Vice President, General Medicine |
12-Jul-2004 |
| Amgen Announces Webcast of Second Quarter Financial Results |
7-Jul-2004 |
| Amgen Names Joshua Ofman Vice President, Reimbursement and Payment Policy |
1-Jul-2004 |
| Amgen's Phase 2 Study of GDNF for Advanced Parkinson's Disease Fails to Meet Primary Endpoint; Six Months of Treatment Showed Biological Effect But No Clinical Improvement |
28-Jun-2004 |
| Phase 3 Study Shows First-Cycle Administration of Neulasta Significantly Lowers Incidence of Infection and Hospitalization |
24-Jun-2004 |
| Amgen Submits Biologics License Application for FDA Approval of Palifermin |
24-Jun-2004 |
| New Two-Year Data Demonstrate That ENBREL Therapy Allowed Significantly More Rheumatoid Arthritis Patients to Achieve Clinical Remission |
10-Jun-2004 |
| Study Results Demonstrate Aranesp Dosed Once Every Three Weeks Achieves Treatment Goals in Managing Anemia in Cancer Patients Receiving Chemotherapy |
8-Jun-2004 |
| Head-to-Head Studies Show Aranesp Dosed Every Two Weeks is Comparable to Epoetin Alfa Dosed Once a Week |
8-Jun-2004 |
| Study Results Demonstrate the Activity of Aranesp in Treating Anemia in Cancer Patients Not Receiving Chemotherapy |
6-Jun-2004 |
| Interim Phase 2 Data Show Panitumumab Has Single-Agent Antitumor Activity in Metastatic Colorectal Cancer; Response Appears Independent of Prior Chemotherapy Regimen |
6-Jun-2004 |
| Catwalk Beauty Vendela To Help Educate Public About Effects of Psoriasis Through ``Making Connections'' Health Education Campaign |
20-May-2004 |
| FDA Approves ENBREL to Treat Psoriasis; New Convenient Treatment Provides Rapid and Significant Relief of Symptoms |
30-Apr-2004 |
| 2004 Cambridge-Boston Recipients of Amgen Award for Science Teaching Excellence Announced |
28-Apr-2004 |
| 2004 Rhode Island Recipients of Amgen Award for Science Teaching Excellence Announced |
28-Apr-2004 |
| Amgen's First Quarter 2004 Adjusted Earnings Per Share Increased 36 Percent to 57 Cents |
22-Apr-2004 |
| 2004 Puerto Rico Recipients of Amgen Award for Science Teaching Excellence Announced |
20-Apr-2004 |
| 2004 Washington Recipients of Amgen Award for Science Teaching Excellence Announced |
19-Apr-2004 |
| 2004 Colorado Recipients of Amgen Award for Science Teaching Excellence Announced |
19-Apr-2004 |
| 2004 Kentucky Recipients of Amgen Award for Science Teaching Excellence Announced |
19-Apr-2004 |
| 2004 California Recipients of Amgen Award for Science Teaching Excellence Announced |
19-Apr-2004 |
| Amgen Announces Webcast of First Quarter Financial Results |
12-Apr-2004 |
| Immunomedics Regains North American Development Rights from Amgen for Epratuzumab |
8-Apr-2004 |
| Sensipar Pivotal Studies in over 700 Patients Published in New England Journal of Medicine |
8-Apr-2004 |
| Amgen Names Rodger Currie Vice President, Government Affairs |
30-Mar-2004 |
| Amgen to Acquire Tularik for $1.3 Billion |
29-Mar-2004 |
| Amgen's First Research and Development Day Highlighted 24 of the Approximately 40 Programs in its Pipeline |
23-Mar-2004 |
| Frank Herringer Nominated for Amgen Board of Directors |
10-Mar-2004 |
| Leonard Schaeffer Joins Amgen's Board of Directors |
9-Mar-2004 |
| FDA Approves Innovative, First-In-Class Treatment for a Serious Complication of Chronic Kidney Disease |
8-Mar-2004 |
| Amgen Opens State-of-the-Art Biotechnology Research Campus |
25-Feb-2004 |
| Amgen Announces Webcast of R&D Day With the Investment Community |
23-Feb-2004 |
| New Phase 3 ENBREL Data Show Psoriasis Patients Achieved a Therapeutic Response From 'Step Down' Dosing Regimen |
7-Feb-2004 |
| Amgen's Fourth Quarter 2003 Adjusted Earnings Per Share Increased 31 Percent to 46 Cents; Full Year 2003 Adjusted Earnings Per Share Increased 37 Percent to $1.90 |
22-Jan-2004 |
| Amgen Announces Webcast of Fourth Quarter and Full Year 2003 Financial Results |
14-Jan-2004 |
| Amgen Names David J. Scott Senior Vice President, General Counsel and Secretary |
13-Jan-2004 |
| Amgen Announces Award for Science Teaching Excellence in Rhode Island |
5-Jan-2004 |
| Amgen Announces Award for Science Teaching Excellence in Colorado |
5-Jan-2004 |
| Amgen Announces Award for Science Teaching Excellence in California |
5-Jan-2004 |
| Amgen Announces Award for Science Teaching Excellence |
5-Jan-2004 |
| Amgen Announces Award for Science Teaching Excellence |
5-Jan-2004 |
| Amgen Announces Award for Science Teaching Excellence in Puerto Rico |
5-Jan-2004 |
| Amgen Announces Award for Science Teaching Excellence |
5-Jan-2004 |
| Amgen Named One of Fortune Magazine's '100 Best Companies to Work For' |
29-Dec-2003 |
| Amgen Forecasts Strong 2004 Financial Performance |
15-Dec-2003 |
| Amgen Names David Beier Senior Vice President, Global Government Affairs |
9-Dec-2003 |
| Phase 3 Data Show Palifermin Improves Patient Reported Outcomes in Cancer Patients and Helps Reduce Hospitalizations and Healthcare Resources |
9-Dec-2003 |
| Analysis of Head-to-Head Studies Shows That Aranesp(R) Dosed Every Two Weeks Offers Similar Results With Less Frequent Administration Compared to Epoetin Alfa |
7-Dec-2003 |
| New Data Suggest Aranesp(R) Benefits Patients Suffering From Anemia of Cancer, Who Are Not Receiving Chemotherapy |
6-Dec-2003 |
| Amgen Announces Webcast of Conference Call to Provide Financial Guidance for 2004 |
1-Dec-2003 |
| Aranesp(R) Administered Once Monthly Maintains Hemoglobin Levels in Patients With Chronic Kidney Disease |
16-Nov-2003 |
| Cinacalcet HCl Phase 3 Results Demonstrate Improvement in the Management of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease |
15-Nov-2003 |
| Amgen Announces Plans for Epratuzumab |
11-Nov-2003 |
| Long-Term Data Support Sustained Efficacy, Tolerability and Increased Vitality For Psoriatic Arthritis Patients Treated With ENBREL and Landmark Phase 3 Data Show Ankylosing Spondylitis Patients Experienced Partial Clinical Remission, Improved Pain Relief |
24-Oct-2003 |
| New Data Show Many Rheumatoid Arthritis Patients Treated With ENBREL Plus Methotrexate Have Experienced Clinical Remission and Most Had No Progression of Joint Damage |
24-Oct-2003 |
| Science Recognizes Amgen as a Top Employer in Annual Survey |
23-Oct-2003 |
| Amgen's Third Quarter 2003 Adjusted Earnings Per Share Increases 56% to 53 Cents |
21-Oct-2003 |
| FDA Approves ENBREL for Once-Weekly Dosing |
20-Oct-2003 |
| Amgen Names H. Christian Fibiger, Ph.D., and Paul G. Pearson, Ph.D., As Vice Presidents to Lead Research Efforts |
16-Oct-2003 |
| Abgenix and Amgen Clarify Responsibilities for ABX-EGF |
14-Oct-2003 |
| Amgen Announces Webcast of Third Quarter 2003 Financial Results |
6-Oct-2003 |
| Amgen Submitted New Drug Applicatioin for Cinacalcet HCI |
8-Sep-2003 |
| Amgen and Biovitrum Sign License Agreement for Innovative Treatment of Type 2 Diabetes and Other Metabolic Disorders |
8-Sep-2003 |
| Amgen Foundation Gives $8 Million in Grants in 2002 |
3-Sep-2003 |
| AMGEN AND GENENTECH SETTLE PATENT DISPUTE |
27-Aug-2003 |
| FDA APPROVES ENBREL AS FIRST THERAPY TO INHIBIT BONE AND JOINT DAMAGE IN PSORIATIC ARTHRITIS PATIENTS |
25-Aug-2003 |
| FDA Approves Enbrel(R) as Treatment to Improve Physical Function in Rheumatoid Arthritis Patients |
31-Jul-2003 |
| Enbrel is First Biologic to Receive FDA Approval for the Treatment of Ankylosing Spondylitis |
24-Jul-2003 |
| TEN THOUSAND PATIENTS ENROLLED IN LANDMARK RHEUMATOID ARTHRITIS STUDY PROGRAM |
9-Jul-2003 |
| Amgen Names Dr. Willard Dere Vice President, Global Inflammation Clinical Development |
8-Jul-2003 |
| Enbrel is First Anti-TNF Therapy Submitted to the FDA for Approval to Treat Psoriasis |
8-Jul-2003 |
| Amgen Announces Webcast of Second Quarter 2003 |
1-Jul-2003 |
| Enbrel is First Biologic Recommended by FDA Panel for Approval to Treat Ankylosing Spondylitis |
24-Jun-2003 |
| Enbrel Combination Therapy Inhibited Progression of Joint Damage and Offered Significant Rheumatoid Arthritis Symptom Relief in New Clinical Study |
20-Jun-2003 |
| In a New Clinical Study, Enbrel Taken Once Weekly Significantly Reduced Pain and Inflammation and Improved Function in Rheumatoid Arthritis Patients |
19-Jun-2003 |
| Enbrel Rapidly and Significantly Improved Back Pain, Mobility and Physical Function in Patients with Ankylosing Spondylitis |
19-Jun-2003 |
| Enbrel Provided Rapid and Significant Relief for Psoriasis Patients in Second Pivotal Study |
19-Jun-2003 |
| New Study Demonstrates Combination Therapy with Enbrel Inhibited Progression of Joint Damage and Offered Significant Symptom Relief for Rheumatoid Arthritis Patients |
16-Jun-2003 |
| New Data Highlight Aranesp Efficacy in Anemic Patients with Lymphoid Cancer |
16-Jun-2003 |
| Amgen Announces First Annual Recipient of the Amgen Prize for Therapeutic Advances in Nephrology |
10-Jun-2003 |
| New Data Suggest Risk of Infection Doubles with Reduced NEUPOGEN Administration |
2-Jun-2003 |
| Aranesp Dosed Once Every Two Weeks Increases Hemoglobin Levels, Improves Fatigue And Reduces Need For Transfusions In Patients With Chemotherapy-Induced Anemia |
1-Jun-2003 |
| Phase 3 Data Suggest Palifermin Significantly Reduces the Duration and Incidence of Oral Mucositis in Cancer Patients |
1-Jun-2003 |
| Interim Phase 2 Data Demonstrate Single-Agent Antitumor Activity With ABX-EGF In Advanced Colorectal Cancer |
31-May-2003 |
| Deborah Norville Launches National Hope Relay in Celebration of People Leading Active Lives Despite their Rheumatoid Arthritis |
28-May-2003 |
| Amgen Appoints Industry Veteran Dr. David R. parkinson To Head oncology Clinical Development |
21-May-2003 |
| 2003 Seattle-Area Recipients of Amgen Award for Science Teaching Excellence Announced |
5-May-2003 |
| 2003 Rhode Island Recipients of Amgen Award for Science Teaching Excellence Announced |
5-May-2003 |
| 2003 Puerto Rico Recipients of Amgen Award for Science Teaching Excellence Announced |
5-May-2003 |
| 2003 Jefferson County Recipients of Amgen Award for Science Teaching Excellence Announced |
5-May-2003 |
| 2003 Colorado Recipients of Amgen Award for Science Teaching Excellence Announced |
5-May-2003 |
| 2003 California Recipients of Amgen Award for Science Teaching Excellence Announced |
5-May-2003 |
| Amgen Announces Webcast of First Quarter 2003 Financial Results |
4-Apr-2003 |
| Amgen Announces $800 Million Investment In Juncos, Puerto Rico For Biotech Manufacturing Center |
20-Mar-2003 |
| Rob Lowe Launches Town Meetings To Help Cancer Patients And Their Loved Ones Understand Chemotherapy And its Side Effects |
3-Mar-2003 |
| Amgen Provides Business Overview Through 2005 |
25-Feb-2003 |
| Amgen Announces Webcast Of Business Review Meeting |
19-Feb-2003 |
| J&J Ordered To Pay Amgen's Costs and Attorneys' Fees In Recent Arbitration |
27-Jan-2003 |
| Amgen Announces Award for Science Teaching Excellence in King and Snohomish Counties |
24-Jan-2003 |
| Amgen Announces Award for Science Teaching Excellence in Rhode Island |
24-Jan-2003 |
| Amgen Announces Award for Science Teaching Excellence |
24-Jan-2003 |
| Amgen Announces Award for Science Teaching Excellence in Colorado |
24-Jan-2003 |
| Amgen Announces Award for Science Teaching Excellence in California |
24-Jan-2003 |
| On an Adjusted Basis, Amgen Reports Fourth Quarter Earnings Per Share Increase 17 Percent to 35 Cents, Full Year 2002 Increase 18 Percent to $1.39 |
23-Jan-2003 |
| Amgen and Immunomedics Announce Emphasis On Development Of AMG 412 (Epratuzumab) As Combination Therapy While Closing Single Agent Trial |
23-Jan-2003 |
| Amgen Announces Positive Results Of Phase 3 Study For rHu-KGF |
23-Jan-2003 |
| Amgen Announces Positive Results of Phase 3 Enbrel Study in Psoriasis |
17-Jan-2003 |
| Amgen Announces Webcast Of Fourth Quarter And Full Year 2002 Financial Results |
15-Jan-2003 |
| Federal Appeals Court Affirms TKT Infringement; Remands Certain Validity Issues to Lower Court |
6-Jan-2003 |
| Epogen - Important Prescribing Information |
2-Jan-2003 |
| Court Dismisses Amgen Reimbursement Challenge |
24-Dec-2002 |
| Amgen Submits Data To FDA Supporting Once-Weekly Dosing Of Enbrel |
23-Dec-2002 |
| FDA Approves Enbrel Manufacturing Facility; Supply For Patients Dramatically Increases |
23-Dec-2002 |
| Data From Study Shows Aranesp Dosed Every Other Week More Cost-Effective Than Epoetin Alfa For Treating Anemia In Chemotherapy Patients |
9-Dec-2002 |
| Amgen Announces Results Of Phase 3 Study Of Enbrel Dosed Once Weekly |
5-Dec-2002 |
| Amgen Announces Webcast Of Conference Call To Provide Financial Guidance For 2003 |
4-Dec-2002 |
| Enbrel Offered To Additional 40,000 Rheumatoid Arthritis, Juvenile Rheumatoid Arthritis And Psoriatic Arthritis Patients |
2-Dec-2002 |
| Amgen Files Suit Seeking Relief From Reimbursement Ruling |
15-Nov-2002 |
| Serono And Amgen Sign License Agreement For Multiple Sclerosis Product |
13-Nov-2002 |
| Amgen Business Review Meeting Resheduled To February 25, 2003 |
5-Nov-2002 |
| First-In-Class Oral Calcimimetic Shown To Reduce Parathyroid Hormone Levels In Chronic Kidney Disease |
3-Nov-2002 |
| New Data On Aranesp(R) Dosed Every Other Week In Anemic Chronic Kidney Disease Patients Presented At 35th Annual Meeting Of The American Society Of Nephrology |
3-Nov-2002 |
| First-In-Class Oral Calcimimetic Shown To Reduce Parathyroid Hormone Levels In Chronic Kidney Disease |
3-Nov-2002 |
| Amgen Comment On New OPPS Rule |
31-Oct-2002 |
| Enbrel(R) Only TNF Receptor With Five Years Sustained Data In Treatment Of Rheumatoid Arthritis |
25-Oct-2002 |
| Enbrel(R) Is First Therapy Shown To Inhibit Bone And Joint Damage In Psoriatic Arthritis Patients |
25-Oct-2002 |
| AMGEN ANNOUNCES POSITIVE STUDY RESULTS OF KINERET(R) IN RHEUMATOID ARTHRITIS DISEASE PROGRESSION AND IN THE TREATMENT OF JUVENILE RHEUMATOID ARTHRITIS |
25-Oct-2002 |
| ENBREL(R) FIRST THERAPY SUBMITTED TO FDA SHOWING INHIBITION OF BONE AND JOINT DAMAGE IN PSORIATIC ARTHRITIS PATIENTS |
24-Oct-2002 |
| Amgen's Third Quarter 2002 Adjusted Earnings Per Share Increase 13% To 34 Cents |
23-Oct-2002 |
| AMGEN FILES WITH FDA FOR USE OF KINERET(R) TO INHIBIT BONE AND JOINT DAMAGE DUE TO RHEUMATOID ARTHRITIS |
22-Oct-2002 |
| Amgen Wins Arbitration and Awarded $150 Million Against Johnson & Johnson |
18-Oct-2002 |
| Amgen And Wyeth Pharmaceuticals Announce Initiation Of Landmark Study In Rheumatoid Arthritis |
17-Oct-2002 |
| Amgen Announces Webcast Of Third-Quarter 2002 Financial Results |
9-Oct-2002 |
| Amgen Submits Data To FDA Supporting Use Of Enbrel To Improve Physical Function In Rheumatoid Arthritis Patients |
26-Sep-2002 |
| Rob Lowe Introduces One-To-One Support Network For New Cancer Patients |
29-Aug-2002 |
| Amgen Announces Filing With FDA For Licensure Of Enbrel Production Facility In Rhode Island |
23-Aug-2002 |
| Second Quarter 2002 Earnings Per Share Increase 27 Percent To 38 Cents |
24-Jul-2002 |
| FDA Approves Amgen's Aranesp For Anemia Associated With Chemotherapy |
22-Jul-2002 |
| Amgen Announces Webcast of Second-Quarter 2002 Financial Results |
19-Jul-2002 |
| Amgen Completes Acquisition Of IMMUNEX |
16-Jul-2002 |
| Amgen Announces $2 Billion Stock Repurchase Plan |
12-Jun-2002 |
| Amgen Receives CPMP Recommendation For European Union Marketing Approval Of Neulasta For The Reduction Of Chemotherapy - Induced Neutropenia |
3-Jun-2002 |
| Amgen Receives CPMP Positive Recommendation For European Union Regulatory Approval Of Aranesp(R)n Oncology |
3-Jun-2002 |
| Amgen Announces Its Registration Statement on Form S-3 Has Been Declared Effective |
31-May-2002 |
| Amgen Files Registration Statement In Connection With Its Zero-Coupon Convertible Notes |
22-May-2002 |
| Aranesp Studies Explore Potential Of New Anemia Treatment Paradigms |
21-May-2002 |
| Amgen Stockholders Approve Issuance of Shares in Connection with Immunex Acquisition |
16-May-2002 |
| Hassan Dayem Will Join Amgen as Senior Vice President and Chief Information Officer |
10-May-2002 |
| Important Drug Warning Counterfeiting of Epogen(R) |
8-May-2002 |
| Amgen to Acquire Filgrastim and Pegfilgrastim in Europe from Roche |
8-May-2002 |
| Amgen Reports First Quarter 2002 Earnings Per Share Increased 14 Percent to 32 Cents |
25-Apr-2002 |
| 2002 Recipients of Amgen Award for Science Teaching Excellence Announced (California) |
22-Apr-2002 |
| 2002 Recipients of Amgen Award for Science Teaching Excellence Announced (Jefferson County, Kentucky) |
22-Apr-2002 |
| 2002 Recipients of Amgen Award for Science Teaching Excellence Announced (Boulder County, Colorado) |
22-Apr-2002 |
| Rob Lowe Launches Awareness Campaign About One Of The Most Dangerous And Unrecognized Side Effects Of Chemotherapy -- Infections |
22-Apr-2002 |
| Amgen Announces Webcast of First-Quarter 2002 Financial Results |
12-Apr-2002 |
| Amgen Signs Multi-Year Agreement With US Oncology for Aranesp, Neulasta and NEUPOGEN |
14-Mar-2002 |
| Amgen Signs Multi-Year Agreement With International Oncology Network for Aranesp, Neulasta and NEUPOGEN |
14-Mar-2002 |
| European Commission Approves Amgen's Kineret for the Treatment of Rheumatoid Arthritis; First Interleukin-1 Receptor Antagonist Represents New Way to Treat RA |
13-Mar-2002 |
| Multimedia Available: What's Your AQ? -- Anemia Quotient -- |
27-Feb-2002 |
| Multimedia Available: Actor Danny Glover Joins Anemia LifeLine to Help Millions of Americans Who Suffer From Anemia Associated With Serious Diseases |
27-Feb-2002 |
| Actor Danny Glover Joins Anemia LifeLine(TM) to Help Millions of Americans Who Suffer from Anemia Associated with Serious Diseases |
27-Feb-2002 |
| Amgen to Receive $2.5 Billion From Offering of Zero-Coupon Senior Convertible Notes |
22-Feb-2002 |
| Amgen to Raise $2.5 Billion From Offering of Zero-Coupon Senior Convertible Notes |
21-Feb-2002 |
| Amgen and Immunex Receive Request for Additional Information From The Federal Trade Commission |
6-Feb-2002 |
| The United States Pharmacopeia Accepts Amgen's Aranesp for Treatment of Chemotherapy-Associated Anemia |
4-Feb-2002 |
| UPDATE: FDA Approves Amgen's Neulasta for Serious and Frequent Chemotherapy Side Effect |
1-Feb-2002 |
| Multimedia Available: FDA Approves Amgen's Neulasta for Serious & Frequent Chemotherapy Side Effect |
31-Jan-2002 |
| FDA Approves Amgen's Neulasta for Serious and Frequent Chemotherapy Side Effect |
31-Jan-2002 |
| Amgen Reports Fourth Quarter and Full Year 2001 Financial Results in Line With Guidance |
23-Jan-2002 |
| Amgen Announces Webcast of Fourth-Quarter and Full Year 2001 Financial Results |
15-Jan-2002 |
| Amgen Announces Award for Science Teaching Excellence; First Year Focusing on Science Teaching |
11-Jan-2002 |
| Amgen Appoints Beth Seidenberg as Senior Vice President -- Development |
10-Jan-2002 |
| Amgen Announces Award for Science Teaching Excellence in California; First Year Focusing on Science Teaching; A Statewide Call for Nominations |
10-Jan-2002 |
| Frank Biondi Joins Amgen's Board of Directors |
8-Jan-2002 |
| Patricia Sueltz Elected to Amgen's Board of Directors |
8-Jan-2002 |
 |
